^
Association details:
Biomarker:Chr amplification(11)(q13)
Cancer:Gastric Adenocarcinoma
Drug Class:Immunotherapy
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

2375 - Comprehensive analysis of immunotherapy-related biomarkers in Chinese patients with gastric adenocarcinoma

Published date:
03/10/2021
Excerpt:
...the biomarkers associated with hyperprogression (HP) to immune checkpoint inhibitors (ICIs) included 11q13 amp, MDM2/MDM4 amp, and CDKN2A/B gene loss, which were identified in 4%, 2% and 2% of patients, respectively.